Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

4.940 -0.400 (-7.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,122,767
Open 5.310
Bid (Size) 4.920 (3)
Ask (Size) 5.100 (8)
Prev. Close 5.340
Today's Range 4.830 - 5.343
52wk Range 2.830 - 20.04
Shares Outstanding 94,362,320
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
Atara Lays Off 20% Of Its Workforce, Issues Update On Cell Therapies
 
Via Benzinga

Performance

YTD
-70.49%
-70.49%
1 Month
+31.73%
+31.73%
3 Month
-6.79%
-6.79%
6 Month
-65.31%
-65.31%
1 Year
-60.19%
-60.19%

More News

Read More
Where Atara Biotherapeutics Stands With Analysts
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Via Benzinga
Mizuho On Atara Biotherapeutics - Distinguish Between Small Numbers And Science Failure
Via Benzinga
Dow Drops Over 100 Points; Verona Pharma Shares Jump
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Atara Biotherapeutics: Q2 Earnings Insights
Via Benzinga
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
From Atara Biotherapeutics, Inc.
Via Business Wire
ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Where Atara Biotherapeutics Stands With Analysts
Via Benzinga
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Drops 100 Points; IronSource Shares Spike Higher
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Via Benzinga
Nasdaq Turns Higher; Delta Air Lines Earnings Miss Estimates
Via Benzinga
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.